top
Search terms
Results 1 - 5 of 5 - ordered by :
Ehjcvp

Despite treatments for secondary prevention, patients with prior myocardial infarction (MI) remain at high risk for recurrent thrombotic events.1 The addition of a P2Y12 receptor antagonist to ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Giulia Magnani, Marc P. Bonaca, Marc S. Sabatine

Date : 01/10/2015 Item size : 188203 bytes
Ehjcvp

The most important public health goal in stroke prevention for patients with atrial fibrillation (AF) is to treat a larger proportion of patients with risk factors for stroke with oral ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Sean D. Pokorney, Christopher B. Granger

Date : 01/04/2015 Item size : 159100 bytes
Ehjcvp

Oral anticoagulation (OAC) is recommended for patients with atrial fibrillation (AF) who are at risk of stroke.1 The CHA2DS2-VASc score, which encompassed a group of common co-morbidities for ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Jo Jo Hai, Hung-Fat Tse

Date : 01/04/2015 Item size : 156814 bytes
Ehjcvp

An index of new research activity in Cardiovascular Pharmacotherapy can be obtained by listing the number of new updates in the 8th edition of Drugs for the Heart2 that covers all the main areas of ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Lionel H. Opie

Date : 01/04/2015 Item size : 144582 bytes
Ehjcvp

Anti-coagulantAnti-plateletAtrial fibrillationBleeding,HaemorrhageNovel oral anti-coagulantStrokeVitamin K antagonistIntroduction In patients with atrial fibrillation (AF), Vitamin K antagonists ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Ariel Dogliotti, Robert P. Giugliano

Date : 01/01/2015